in 2013 studied highly purified JAK2 V617F HSCs from a JAK2 V617F mouse model with an ET phenotype, and observed that the mutation reduced HSC numbers, but that early progenitors exhibited increased proliferation and differentiation (105). The gene discussed is JAK2; the disease is essential thrombocythemia.